CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), an oncology company in the clinical stage, announced today the addition of Dr. Thomas J. Schall, a seasoned biotech leader, to its Board of Directors. Dr. Schall brings a wealth of experience from his tenure as Chairman, CEO, and Founder of ChemoCentryx (NASDAQ:CCXI), which was acquired by Amgen (NASDAQ:AMGN) in 2022.
Ben Zeskind, CEO of Immuneering, expressed the company's honor in welcoming Dr. Schall to the board. Zeskind highlighted Dr. Schall's 25-year track record in drug discovery and development as a valuable asset for Immuneering's mission to create broad-spectrum cancer therapies.
Dr. Schall expressed his enthusiasm for joining Immuneering during a pivotal phase as the company progresses its pipeline of universal-RAS/RAF cancer medicines. He looks forward to contributing to the strategic direction of the company and supporting the development of new cancer treatments.
With a history of significant contributions to the field of chemokine system function and activities, Dr. Schall's expertise is expected to be highly influential for Immuneering. His background includes roles at DNAX Research Institute and Genentech, Inc., and he holds a Ph.D. in cancer biology from Stanford University.
Immuneering is focused on developing universal-RAS/RAF medicines for a wide range of cancer patients. Its lead product candidate, IMM-1-104, is an oral inhibitor currently in a Phase 1/2a study targeting advanced solid tumors with RAS mutations. Another candidate, IMM-6-415, is preparing for a Phase 1/2a study for tumors with RAS or RAF mutations. The company's approach aims to inhibit the MAPK pathway cyclically, impacting cancer cells while sparing healthy cells.
This announcement is based on a press release statement from Immuneering Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.